Ionis Pharmaceuticals received FDA approval for Dawnzera (donidalorsen), a prophylactic therapy targeting hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder characterized by swelling attacks. This approval follows positive phase III data demonstrating significant attack rate reductions and a favorable safety profile. Dawnzera expands treatment options for HAE patients and features a user-friendly autoinjector allowing dosing intervals up to eight weeks.